You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics
SBC: NEUROP, INC. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of small near-infrared laser system capable of improving immune respo
SBC: SEMINEX CORPORATION Topic: NIAIDDESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Feasibility of Non-surgical Implant Adjustment
SBC: Apto Orthopaedics Corportation Topic: NIAMSDESCRIPTION (provided by applicant): While minimally invasive surgery has transformed the practice of surgery, access to implants for removal or alteration still requires surgery which generates risk and high cost. A next-generation approach is non-invasive, where implants are adjusted without an incision. There are clear applications in all fields of surgery, but particulary in orthopaedics wher ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NCIDESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal
SBC: BESSOR PHARMA, LLC Topic: NCIDESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis
SBC: DYNUPOL, INC. Topic: NCIProject Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes
SBC: Jenesis Biosciences LLC Topic: NIDDKDESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Smartphone Help for DWI Offenders and Their Families: A B-SMART App
SBC: KLEIN BUENDEL, INC. Topic: NIAAADESCRIPTION (provided by applicant): Driving while intoxicated (DWI) remains a substantial and preventable source of morbidity and mortality in the United States. A variety of sanctions and interventions have been attempted to reduce DWI in the U.S., including enhanced DWI enforcement efforts, stricter drunk driving laws, responsible alcohol beverage service training, and alcohol treatment. The Ig ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
CMV Vectored Herpes Simplex Vaccine
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Testing Smad7-based biologics for treating chronic wounds
SBC: Taiga Biotechnologies, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health